These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29900477)

  • 21. Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.
    Alnaqbi KA; Al Adhoubi N; Aldallal S; Al Emadi S; Al-Herz A; El Shamy AM; Hannawi S; Omair MA; Saad SA; Kvien TK
    BioDrugs; 2024 May; 38(3):449-463. PubMed ID: 38402494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
    Schaeverbeke T; Pham T; Richez C; Wendling D
    Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
    Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
    [No Abstract]   [Full Text] [Related]  

  • 27. Biosimilars: clinical interpretation and implications for drug development.
    Mysler E
    Curr Rheumatol Rep; 2015 Feb; 17(2):8. PubMed ID: 25618574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biosimilars].
    Burmester GR; Müller-Ladner U
    Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433
    [No Abstract]   [Full Text] [Related]  

  • 36. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars in childhood chronic rheumatic diseases: friend or foe?
    Maccora I; Simonini G
    Lancet Rheumatol; 2024 Jul; 6(7):e413-e414. PubMed ID: 38843857
    [No Abstract]   [Full Text] [Related]  

  • 39. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.